[6-min read] Q&A with Kate Kincaid, Therapist & Mother
[5-min read] MAPS’ latest clinical trial paves the way for FDA approval.
[6-min read] Q&A with Raad Seraj, Angel Investor & Founder
[5-min read] AI model accurately predicts psilocybin treatment responses.
[6-min read] Q&A with Julian Vayne, Occultist & Scholar
[5-min read] One dose of psilocybin relieves depression for weeks in Usona trial.
[6-min read] Q&A with Wilhelmina De Castro, Therapist & Founder
[5-min read] Study suggests MDMA buffers against “bad trips” on psilocybin or LSD.
[6-min read] Q&A with Hunt Priest, Episcopal Priest & Director
[5-min read] Presidential candidates speak out on psychedelic policy reform.
[5-min read] Q&A with Ian-Michael Hébert, Eco Resort Developer
[5-min read] Companies are adding psychedelic therapy to their employee benefit plans.
